Diagnosis and therapy are walking together on radiopeptides' avenue

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 4, 2011, Pages 605-612

  Mansi, Luigi ^a   Virgolini, Irene ^b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LANREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[1 DEXTRO PHENYLALANINE][3 TYROSINE] LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[1 DEXTRO PHENYLALANINE][3 TYROSINE] Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID OCTREOTIDE[3 TYROSINE] Y 90; ANGIOPEPTIN; BEVACIZUMAB; COPPER 64; EVEROLIMUS; FLUORINE 18; GALLIUM 68; INTEGRIN RECEPTOR; LUTETIUM 177; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; RAPAMYCIN; SOMATOSTATIN RECEPTOR; SUNITINIB; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90;

BRAIN TUMOR; CANCER DIAGNOSIS; CANCER SURVIVAL; CANCER THERAPY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG UPTAKE; HUMAN; INSULINOMA; ISOTOPE LABELING; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE;

ANIMALS; HUMANS; NEUROENDOCRINE TUMORS; PEPTIDES; RADIOACTIVE TRACERS; RADIOISOTOPES; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 79953694765     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-011-1762-8     Document Type: Review

References (36)

1. Jiang L, Miao Z, Kimura RH, Liu H, Cochran JR, Culter CS, Bao A, Li P, Cheng Z. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy. Eur J Nucl Med Mol Imaging 2010. doi: 10.1007/s00259-010-1684-x.
2. D Heute H Kostron E von Guggenberg S Ingorokva M Gabriel G Dobrozemsky G Stockhammer IJ Virgolini 2010 Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC J Nucl Med 51 3 397 400 20150267 10.2967/jnumed.109.072819 1:CAS:528:DC%2BC3cXksVylsr4%3D
3. MK Gagnon SH Hausner J Marik CK Abbey JF Marshall JL Sutcliffe 2009 High-throughput in vivo screening of targeted molecular imaging agents Proc Natl Acad Sci U S A 106 42 17904 17909 19815497 10.1073/pnas.0906925106 1:CAS:528:DC%2BD1MXhtl2rurvI
4. A Lupetti PH Nibbering MM Welling EK Pauwels 2003 Radiopharmaceuticals: new antimicrobial agents Trends Biotechnol 21 2 70 73 12573855 10.1016/S0167-7799(02)00032-X 1:CAS:528:DC%2BD3sXptlynsg%3D%3D (Pubitemid 36165006)
5. H Jang FT Arce S Ramachandran R Capone R Azimova BL Kagan R Nussinov R Lal 2010 Truncated beta-amyloid peptide channels provide an alternative mechanism for Alzheimer's disease and Down syndrome Proc Natl Acad Sci U S A 107 14 6538 6543 20308552 10.1073/pnas.0914251107 1:CAS:528:DC%2BC3cXkslymsrg%3D
6. T Olafsen AM Wu 2010 Antibody vectors for imaging Semin Nucl Med 40 3 167 181 20350626 10.1053/j.semnuclmed.2009.12.005
7. ES Olson T Jiang TA Aguilera QT Nguyen LG Ellies M Scadeng RY Tsien 2010 Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases Proc Natl Acad Sci U S A 107 9 4311 4316 20160077 10.1073/pnas.0910283107 1:CAS:528:DC%2BC3cXjsFWiurw%3D
8. J Segala DM Engelman YK Reshetnyak OA Andreev 2009 Accurate analysis of tumor margins using a fluorescent pH low insertion peptide (pHLIP) Int J Mol Sci 10 8 3478 3487 20111691 10.3390/ijms10083478 1:CAS:528:DC%2BD1MXhtVWmtr%2FJ
9. Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR. A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 2010 Feb 4
10. IJ Virgolini M Gabriel E von Guggenberg D Putzer D Kendler C Decristoforo 2009 Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours Eur J Cancer 45 Suppl 1 274 291 19775625 10.1016/S0959-8049(09)70042-5
11. G Mariani PA Erba A Signore 2006 Receptor-mediated tumor targeting with radiolabeled peptides: there is more to it than somatostatin analogs J Nucl Med 47 12 1904 1907 17138731 1:CAS:528:DC%2BD2sXksFKhsg%3D%3D (Pubitemid 47544976)
12. V Ambrosini P Tomassetti R Franchi S Fanti 2010 Imaging of NETs with PET radiopharmaceuticals Q J Nucl Med Mol Imaging 54 1 16 23 20168283 1:STN:280:DC%2BC3c7hvVKrsw%3D%3D
13. M Gabriel C Decristoforo D Kendler G Dobrozemsky D Heute C Uprimny P Kovacs E Von Guggenberg R Bale IJ Virgolini 2007 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 4 508 518 17401086 10.2967/jnumed.106.035667 1:CAS:528:DC%2BD2sXhtVert7jF (Pubitemid 47571404)
14. T Traub-Weidinger E Von Guggenberg G Dobrozemsky D Kendler W Eisterer R Bale D Putzer M Gabriel I Virgolini 2010 Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography Q J Nucl Med Mol Imaging 54 1 52 60 20168286 1:STN:280:DC%2BC3c7hvVKrtg%3D%3D
15. R King MB Surfraz C Finucane SC Biagini PJ Blower SJ Mather 2009 99mTc-HYNIC-gastrin peptides: assisted coordination of 99mTc by amino acid side chains results in improved performance both in vitro and in vivo J Nucl Med 50 4 591 598 19289435 10.2967/jnumed.108.058289 1:CAS:528:DC%2BD1MXltVOgtrg%3D
16. CA Boswell CA Regino KE Baidoo KJ Wong DE Milenic JA Kelley CC Lai MW Brechbiel 2009 A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging Bioorg Med Chem 17 2 548 552 19101152 10.1016/j.bmc.2008.11.073 1:CAS:528:DC%2BD1MXhtFerur4%3D
17. GL Cascini V Cuccurullo L Mansi 2010 The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology Q J Nucl Med Mol Imaging 54 1 24 36 20168284 1:STN:280: DC%2BC3c7hvVKrsA%3D%3D
18. D Putzer M Gabriel D Kendler B Henninger M Knoflach A Kroiss E Vonguggenberg B Warwitz IJ Virgolini 2010 Comparison of (68)Ga-DOTA-Tyr(3)- octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients Q J Nucl Med Mol Imaging 54 1 68 75 20168288 1:STN:280:DC%2BC3c7hvVKrtA%3D%3D
19. R Haubner B Kuhnast C Mang WA Weber H Kessler HJ Wester M Schwaiger 2004 [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates Bioconjug Chem 15 1 61 69 14733584 10.1021/bc034170n 1:CAS:528:DC%2BD3sXpslWns7Y%3D (Pubitemid 38165981)
20. W Cai X Chen 2008 Multimodality molecular imaging of tumor angiogenesis J Nucl Med 49 Suppl 2 113S 128S 18523069 10.2967/jnumed.107.045922 1:CAS:528:DC%2BD1cXotFahu74%3D (Pubitemid 351948040)
21. EP Krenning PP Kooij WH Bakker WA Breeman PT Postema DJ Kwekkeboom HY Oei M de Jong TJ Visser AE Reijs, et al. 1994 Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history Ann N Y Acad Sci 733 496 506 7978900 10.1111/j.1749-6632.1994.tb17300.x 1:STN:280:DyaK2M%2FmvFKjuw%3D%3D
22. DJ Kwekkeboom EP Krenning R Lebtahi P Komminoth B Kos-Kudła WW de Herder U Plöckinger 2009 ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs Neuroendocrinology 90 2 220 226 19713714 10.1159/000225951 1:CAS:528:DC%2BD1MXhtVGgs7vE
23. DJ Kwekkeboom WW de Herder CHJ van Eijck BL Kam M van Essen JJM Teunissen EP Krenning 2010 Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumours Semin Nucl Med 40 78 88 20113677 10.1053/j.semnuclmed.2009.10.004
24. M Gabriel U Andergassen D Putzer A Kroiss D Waitz E von Guggenberg D Kendler IJ Virgolini 2010 Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients Q J Nucl Med Mol Imaging 54 92 99 20168291 1:STN:280: DC%2BC3c7hvVKruw%3D%3D
25. F Forrer H Uusijärvi D Storch HR Maecke J Mueller-Brand 2005 Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumours after treatment with 90Y-DOTATOC J Nucl Med 46 1310 1316 16085587 1:CAS:528:DC%2BD28XitVGlsLc%3D (Pubitemid 43733480)
26. E Seregni M Maccauro A Coliva MR Castellani E Bajetta G Aliberti C Vellani C Chiesa A Martinetti A Bogni E Bombardieri 2010 Treatment with tandem [(90)Y]DOTA-TATE an [(177)Lu]DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results Q J Nucl Med Mol Imaging 54 84 91 20168290 1:STN:280:DC%2BC3c7hvVKrug%3D%3D
27. DJ Kwekkeboom WW de Herder BL Kam CH van Eijck M van Essen PP Kooij RA Feelders MO van Aken EP Krenning 2008 Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival J Clin Oncol 26 2124 2130 18445841 10.1200/JCO.2007.15.2553 1:CAS:528:DC%2BD1cXms1Ort7s%3D
28. JB Cwikla A Sankowski N Seklecka JR Buscombe A Nasierowska-Guttmejer KG Jeziorski R Mikolajczak D Pawlak K Stepien J Walecki 2010 Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study Ann Oncol 21 4 787 794 19833821 10.1093/annonc/mdp372 1:STN:280: DC%2BC3c3htFGkug%3D%3D
29. C Kratochwil FL Giesel R López-Benítez N Schimpfky K Kunze M Eisenhut HU Kauczor U Haberkorn 2010 Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors Clin Cancer Res 16 10 2899 2905 20460485 10.1158/1078-0432.CCR-10-0004 1:CAS:528:DC%2BC3cXlvF2hs7w%3D
30. GS Limouris A Chatziioannou D Kontogeorgakos D Mourikis M Lyra P Dimitriou A Stavraka A Gouliamos L Vlahos 2008 Selective hepatic arterial infusion of In-111-DTPA-Phe1-octreotide in neuroendocrine liver metastases Eur J Nucl Med Mol Imaging 35 1827 1837 18536916 10.1007/s00259-008-0779-0 1:CAS:528:DC%2BD1cXhtFCjtbzJ
31. MKG McStay D Maudgil M Williams JM Tibballs AF Watkinson ME Caplin JR Buscombe 2005 Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy Radiology 237 718 726 16192318 10.1148/radiol.2372041203 (Pubitemid 41507917)
32. M Kalinowski M Dressler A König M El-Sheik A Rinke H Höffken TM Gress R Arnold KJ Klose HJ Wagner 2009 Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study Digestion 79 3 137 142 19307736 10.1159/000209849
33. A Rinke HH Müller C Chade-Brittinger KJ Klose P Barth M Wied C Mayer B Aminossadati UF Pape M Bläker J Harder C Arnold T Gress R Arnold PROMID Study Group 2009 Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group J Clin Oncol 27 28 4656 4663 19704057 10.1200/JCO.2009.22.8510 1:CAS:528:DC%2BD1MXhtlGgtbnJ
34. M Gabriel A Oberauer G Dobrozemsky C Decristoforo D Putzer D Kendler C Uprimny P Kovacs R Bale IJ Virgolini 2009 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy J Nucl Med 50 9 1427 1434 19690033 10.2967/jnumed.108.053421 1:CAS:528: DC%2BD1MXhtFOrtbrN
35. MT Madsen DL Bushnell ME Juweid Y Menda MS O'Dorisio T O'Dorisio IM Besse 2006 Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model J Nucl Med 47 4 660 667 16595501 (Pubitemid 46768468)
36. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC. Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting. J Clin Oncol 2011 Jan 24 [Epub ahead of print].